Version history

{
  "session_id": "sess_SDA-BIOMNI-BINDER_D-0657a9ed",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Computational De Novo Protein Binder Design for α-Synuclein Aggregation Inhibition\n\n---\n\n## Hypothesis 1: Structure-Based Targeting of the NACore β-Sheet Interface\n\n**Description:** Computational design targeting the pre-structured NACore (residues ~68–78), which forms the steric zipper and β-sheet core essential for aggregation nucleation, using high-resolution cryo-EM fibril structures (e.g., PDB 6H6B) as templates for binder docking. Designed binders would occupy the self-complementary interface that drives β-strand stacking during oligomerization.\n\n**Target:** α-Synuclein (SNCA), NACore residues 68–78\n\n**Confidence:** 0.78\n\n**Rationale:** The NACore is the minimal aggregation-prone segment; mutational disruption (e.g., G73A) and peptide inhibitors demonstrate that targeting this interface blocks fibril formation. However, αS's intrinsic disorder outside the core may reduce the precision of structure-based design.\n\n---\n\n## Hypothesis 2: Oligomer-Specific Surface Epitope Blockade\n\n**Description:** Computational design of binders recognizing transient quaternary surfaces unique to spherical αS oligomers—distinct from monomeric αS or mature fibrils—exploiting the \"toxic oligomer\" hypothesis. These binders would sterically occlude membrane-permeabilizing interfaces or block the templated seeding surface that propagates pathology.\n\n**Target:** α-Synuclein oligomer-specific epitopes (conformational)\n\n**Confidence:** 0.65\n\n**Rationale:** Conformation-specific antibodies (e.g., ASyn295, NJ001) validate that oligomers display unique surfaces. However, the transient nature of oligomers makes structural characterization difficult, limiting accurate computational targeting.\n\n---\n\n## Hypothesis 3: Cryptic Pocket Stabilization to Prevent Conformational Conversion\n\n**Description:** De novo design of minibinders (e.g., 40–80 residue scaffolds) targeting cryptic allosteric pockets on monomeric αS that, when stabilized, trap the protein in a non-aggregation-competent conformation. Using ensemble-based modeling or AlphaFold2-generated conformational states to identify pockets that, upon binder engagement, shift the monomer ensemble away from β-sheet-prone states.\n\n**Target:** α-Synuclein monomer cryptic binding sites (dynamic)\n\n**Confidence:** 0.58\n\n**Rationale:** αS monomers adopt heterogeneous conformations, and ligand-induced stabilization of specific states has precedent (e.g., EGCG remodels aggregates). However, designing for intrinsically disordered targets remains computationally challenging, as pocket identification depends on sampled conformational states.\n\n---\n\n## Hypothesis 4: Rational Design of Aggregation Competing Sequences\n\n**Description:** Incorporation of computed \"aggregation-blocking sequences\" into designed scaffolds that function as dominant-negative competitors. These sequences would mimic the aggregation interface but integrate into designed binder scaffolds rather than fibrils, effectively sequestering wild-type αS or acting as \"molecular sponges\" that cap growing fibril ends.\n\n**Target:** α-Synuclein C-terminal aggregation interface (residues ~100–140)\n\n**Confidence:** 0.70\n\n**Rationale:** The C-terminal region facilitates cross-β interactions, and C-terminal fragments accelerate aggregation. Peptide-based inhibitors derived from this region show efficacy in cellular models. Designed scaffolds could improve stability and cellular delivery compared to free peptides.\n\n---\n\n**Key Challenges Across Hypotheses:** Blood-brain barrier penetration, immunogenicity of de novo proteins, potential off-target aggregation of designed binders themselves, and validation of mechanism in physiologically relevant systems.",
  "tokens_used": "920"
}